Analyst Ratings For Fate Therapeutics Inc (NASDAQ:FATE)
Today, Leerink Swann initiated coverage on Fate Therapeutics Inc (NASDAQ:FATE) with a Outperform.
There are 6 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Fate Therapeutics Inc (NASDAQ:FATE) is Buy with a consensus target price of $19.50 per share, a potential 16.70% upside.
Some recent analyst ratings include
- 3/28/2019-Fate Therapeutics Inc (NASDAQ:FATE) has coverage initiated with a Outperform rating
- 1/3/2019-Fate Therapeutics Inc (NASDAQ:FATE) gets downgraded to Equal by Stephens
- 11/5/2018-Fate Therapeutics Inc (NASDAQ:FATE) has coverage initiated with a Buy ➝ Buy rating and $17.00 price target
- 9/25/2018-Fate Therapeutics Inc (NASDAQ:FATE) had its Overweight rating reiterated by Piper Jaffray Companies with a $23.00 price target
- 8/7/2018-Fate Therapeutics Inc (NASDAQ:FATE) had its Hold rating reiterated by HC Wainwright with a $12.00 price target
- On 3/21/2019 J Scott Wolchko, Insider, sold 20,000 with an average share price of $17.61 per share and the total transaction amounting to $352,200.00.
- On 3/1/2019 Cindy Tahl, General Counsel, sold 25,000 with an average share price of $16.15 per share and the total transaction amounting to $403,750.00.
- On 2/25/2019 Cindy Tahl, General Counsel, sold 25,000 with an average share price of $16.07 per share and the total transaction amounting to $401,750.00.
- On 1/30/2019 Amir Nashat, Director, sold 53,017 with an average share price of $14.16 per share and the total transaction amounting to $750,720.72.
- On 1/28/2019 Amir Nashat, Director, sold 70,000 with an average share price of $13.78 per share and the total transaction amounting to $964,600.00.
- On 1/25/2019 Amir Nashat, Director, sold 90,000 with an average share price of $14.14 per share and the total transaction amounting to $1,272,600.00.
- On 1/18/2019 Amir Nashat, Director, sold 39,483 with an average share price of $16.28 per share and the total transaction amounting to $642,783.24.
About Fate Therapeutics Inc (NASDAQ:FATE)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Recent Trading Activity for Fate Therapeutics Inc (NASDAQ:FATE)
Shares of Fate Therapeutics Inc closed the previous trading session at 16.71 −0.10 0.59% with 575100 shares trading hands.